EP4245320 - METHODS AND COMPOSITIONS FOR IMMUNE PROTECTION AGAINST EXTRA-INTESTINAL PATHOGENIC E. COLI [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 03.05.2024 Database last updated on 31.08.2024 | |
Former | The application has been published Status updated on 18.08.2023 | Most recent event Tooltip | 05.07.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states GlaxoSmithKline Biologicals S.A. Rue de l'Institut, 89 1330 Rixensart / BE | For all designated states Janssen Pharmaceuticals, Inc. 1125 Trenton-Harbourton Road Titusville, NJ 08560 / US | [2023/38] | Inventor(s) | 01 /
POOLMAN, Jan Theunis 2011 CT Haarlem / NL | 02 /
ABBANAT, Darren Robert New York, 12518 / US | 03 /
YON, Patricia Ibarra 4112 Solothum / CH | 04 /
HERMANS, Peter Wilhelmus 6852 PG Huissen / NL | 05 /
KOWARIK, Michael Thomas 8055 Zurich / CH | 06 /
WETTER, Michael Lukas 8047 Zurich / CH | 07 /
KEMMLER, Stefan Jochen 8048 Zurich / CH | 08 /
HAUPTLE, Micha Andres 8952 Zurich-Schlieren / CH | 09 /
GAMBILLARA, Veronica 8706 Meilen / CH | 10 /
MALLY, Manuela 8105 Watt / CH | 11 /
JACQUEMYN, Bert 2800 Mechelen / BE | [2023/38] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2023/38] | Application number, filing date | 23176994.4 | 24.08.2016 | [2023/38] | Priority number, date | US201562209091P | 24.08.2015 Original published format: US 201562209091 P | US201562210655P | 27.08.2015 Original published format: US 201562210655 P | [2023/38] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP4245320 | Date: | 20.09.2023 | Language: | EN | [2023/38] | Type: | A3 Search report | No.: | EP4245320 | Date: | 22.11.2023 | Language: | EN | [2023/47] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 23.10.2023 | Classification | IPC: | A61K39/02, C08B37/00, A61K39/00, A61K39/108, A61K47/64, A61P31/04 | [2023/47] | CPC: |
A61K39/0258 (EP,IL,KR,US);
A61K39/00 (IL);
A61K39/385 (US);
A61K47/6415 (EP,KR,US);
A61K47/646 (EP,KR,US);
A61P29/00 (KR);
A61P31/04 (EP,US);
C08B37/0063 (EP,IL,KR,US);
A61K2039/545 (EP,IL,KR,US);
A61K2039/55583 (EP,IL,KR,US);
A61K2039/6037 (EP,IL,KR,US);
A61K2039/6087 (EP,IL,KR,US);
|
Former IPC [2023/38] | A61K47/64 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/23] |
Former [2023/38] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | VERFAHREN UND ZUSAMMENSETZUNGEN ZUM IMMUNSCHUTZ GEGEN EXTRAINTESTINALE PATHOGENE E. COLI | [2023/38] | English: | METHODS AND COMPOSITIONS FOR IMMUNE PROTECTION AGAINST EXTRA-INTESTINAL PATHOGENIC E. COLI | [2023/38] | French: | MÉTHODES ET COMPOSITIONS POUR UNE PROTECTION IMMUNITAIRE CONTRE E. COLI PATHOGÈNE EXTRA-INTESTINALE | [2023/38] | Examination procedure | 29.04.2024 | Amendment by applicant (claims and/or description) | 29.04.2024 | Examination requested [2024/23] | 29.04.2024 | Date on which the examining division has become responsible | Parent application(s) Tooltip | EP16760616.9 / EP3341016 | Fees paid | Renewal fee | 02.06.2023 | Renewal fee patent year 03 | 02.06.2023 | Renewal fee patent year 04 | 02.06.2023 | Renewal fee patent year 05 | 02.06.2023 | Renewal fee patent year 06 | 02.06.2023 | Renewal fee patent year 07 | 02.06.2023 | Renewal fee patent year 08 | 04.07.2024 | Renewal fee patent year 09 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2009104074 (GLYCOVAXYN AG [CH], et al) [A] 1-12 * page 17, lines 3-11 * * claims 25, 26 * * example 10 * * claims 5,8 * * page 22, lines 29-30 *; | [A]WO2014037585 (GLYCOVAXYN AG [CH]) [A] 1-12 * paragraph [0007] * * paragraph [0009] * * paragraph [0014] *; | [AP]WO2015124769 (GLYCOVAXYN AG [CH]) [AP] 1-12 * page 103 - page 104; table 6 * * examples 9, 11, 12 * * claims 1, 4, 5, 6 * * paragraph [0264] *; | [A] - A. CROSS ET AL, "Safety And Immunogenicity Of A Polyvalent Escherichia Coli Vaccine In Human Volunteers", JOURNAL OF INFECTIOUS DISEASES. JID, CHICAGO, IL., (19941001), vol. 170, no. 4, doi:10.1093/infdis/170.4.834, ISSN 0022-1899, pages 834 - 840, XP055311603 [A] 1-12 * abstract * * page 834, column r, paragraph 5 - page 835, column l, paragraph 1 * * table 2 * * table 3 * DOI: http://dx.doi.org/10.1093/infdis/170.4.834 | [A] - CRYZ S J ET AL, "Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine", VACCINE, ELSEVIER LTD, GB, (19950101), vol. 13, no. 5, doi:10.1016/0264-410X(94)00009-C, ISSN 0264-410X, pages 449 - 453, XP004057719 [A] 1-12 * abstract * * page 450, column r, paragraph 3 * DOI: http://dx.doi.org/10.1016/0264-410X(94)00009-C | [A] - MARIO F FELDMAN ET AL, "Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 102, no. 8, doi:10.1073/PNAS.0500044102, ISSN 0027-8424, (20050222), pages 3016 - 3021, (20050209), XP009121034 [A] 1-12 * abstract * DOI: http://dx.doi.org/10.1073/pnas.0500044102 | [A] - B. A. ROGERS ET AL, "Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, (20110101), vol. 66, no. 1, doi:10.1093/jac/dkq415, ISSN 0305-7453, pages 1 - 14, XP055056619 [A] 1-12 * abstract * DOI: http://dx.doi.org/10.1093/jac/dkq415 | [AP] - VAN DEN DOBBELSTEEN GERMIE P J M ET AL, "Immunogenicity and safety of a tetravalentE. coliO-antigen bioconjugate vaccine in animal models", VACCINE, ELSEVIER LTD, GB, (20160706), vol. 34, no. 35, doi:10.1016/J.VACCINE.2016.06.067, ISSN 0264-410X, pages 4152 - 4160, XP029644969 [AP] 1-12 * the whole document * DOI: http://dx.doi.org/10.1016/j.vaccine.2016.06.067 | by applicant | GB2220211 | US5057540 | WO2006119987 | WO2007109812 | WO2007109813 | WO2009104074 | WO2014057109 | WO2015124769 | - JOHNSON et al., J Lab Clin Med, (20020000), vol. 139, no. 3, pages 155 - 162 | - KOHLER et al., Int J MedMicrobiol, (20110000), vol. 301, no. 8, pages 642 - 647 | - FOXMAN, Am J Med, (20020000), vol. 1A, pages 5S - 13S | - RUSSO et al., Microbes Infect, (20030000), vol. 5, no. 5, pages 449 - 456 | - SCHITO et al., Int. J. Antimicrob. Agents, (20090000), vol. 34, no. 5, pages 407 - 413 | - PITOUT et al., Expert Rev. Anti. Infect. Ther, (20120000), vol. 10, no. 10, pages 1165 - 1176 | - JOHNSON et al., Antimicrob Agents Chemother, (20100000), vol. 54, no. 1, pages 546 - 550 | - ROGERS et al., J Antimicrob Chemother, (20110000), vol. 66, no. 1, pages 1 - 14 | - ROGERS et al., Antimicrob Agents Chemother. 2014, (20110000), vol. 58, no. 9, pages 4997 - 5004 | - STENUTZ et al., FEMS Microbial Rev, (20060000), vol. 30, pages 382 - 403 | - RUSSO et al., Vaccine, (20070000), vol. 25, pages 3859 - 3870 | - LIPSITCH, Emerging Infectious Diseases, (19990000), vol. 5, pages 336 - 345 | - STOUTE et al., N. Engl. J. Med, (19970000), vol. 336, pages 86 - 91 | - IHSSEN et al., Microbial Cell Factories, (20100000), vol. 9, no. 61, page 61 | - LUKAC et al., Infect Immun, (19880000), vol. 56, pages 3095 - 3098 | - HO et al., Hum Vaccin, (20060000), vol. 2, pages 89 - 98 | - PAWLOWSKI et al., vaccine, (20000000), vol. 18, pages 1873 - 1885 | - ROBBINS et al., Proc Natl Acad Sci USA, (20090000), vol. 106, pages 7974 - 7978 | - SARASWAT et al., Biomed. Res. Int, (20130000), pages 1 - 18 | - DATSENKOWANNER, Proc Natl Acad Sci USA, (20000000), vol. 97, pages 6640 - 6645 | - KIM et al., Clin Diagn Lab Immunol, (20030000), vol. 315, no. 4, pages 616 - 145 | - JOHNSON et al., JLab Clin Med, (20020000), vol. 139, no. 3, pages 155 - 162 | - ROGERS et al., JAntimicrob Chemother, (20110000), vol. 66, no. 1, pages 1 - 14 | - BANERJEE et al., Antimicrob Agents Chemother, (20140000), vol. 58, no. 9, pages 4997 - 5004 | - PAWLOWSKI et al., Vaccine, (20000000), vol. 18, pages 1873 - 1885 | WO2007US64857 | WO2007US64858 | WO2015EP53739 |